Kymera Therapeutics (NASDAQ:KYMR) Given New $128.00 Price Target at UBS Group

Kymera Therapeutics (NASDAQ:KYMR) had its price target increased by UBS Group from $90.00 to $128.00 in a research report sent to investors on Tuesday,Benzinga reports. UBS Group currently has a buy rating on the stock.

Several other research firms also recently issued reports on KYMR. Bank of America upped their price objective on Kymera Therapeutics from $71.00 to $112.00 and gave the stock a “buy” rating in a report on Tuesday, December 9th. B. Riley Financial boosted their target price on Kymera Therapeutics from $80.00 to $117.00 and gave the stock a “buy” rating in a research report on Monday, December 22nd. Citigroup upped their price target on Kymera Therapeutics from $110.00 to $120.00 and gave the company a “buy” rating in a research note on Monday. Morgan Stanley reiterated an “overweight” rating and issued a $123.00 price target on shares of Kymera Therapeutics in a report on Thursday, February 26th. Finally, Piper Sandler lifted their price objective on Kymera Therapeutics from $125.00 to $140.00 and gave the stock an “overweight” rating in a research report on Thursday, February 26th. One investment analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $119.50.

Kymera Therapeutics Stock Down 4.2%

Shares of NASDAQ:KYMR opened at $86.35 on Tuesday. The firm has a market cap of $7.05 billion, a P/E ratio of -23.46 and a beta of 2.20. Kymera Therapeutics has a 12 month low of $19.44 and a 12 month high of $103.00. The company’s 50-day moving average price is $78.69 and its two-hundred day moving average price is $66.27.

Kymera Therapeutics (NASDAQ:KYMR) last announced its earnings results on Thursday, February 26th. The company reported ($0.97) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.77) by ($0.20). Kymera Therapeutics had a negative return on equity of 28.71% and a negative net margin of 794.04%.The company had revenue of $2.87 million for the quarter, compared to analyst estimates of $14.80 million. During the same quarter in the previous year, the company posted ($0.88) earnings per share. Kymera Therapeutics’s revenue for the quarter was down 60.8% on a year-over-year basis. As a group, equities analysts predict that Kymera Therapeutics will post -2.79 earnings per share for the current fiscal year.

Insider Activity at Kymera Therapeutics

In other Kymera Therapeutics news, Director Jeffrey W. Albers sold 5,000 shares of Kymera Therapeutics stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $89.76, for a total transaction of $448,800.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Jared Gollob sold 49,307 shares of the business’s stock in a transaction dated Monday, December 8th. The shares were sold at an average price of $88.67, for a total value of $4,372,051.69. Following the completion of the transaction, the insider directly owned 109,992 shares of the company’s stock, valued at approximately $9,752,990.64. The trade was a 30.95% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 450,895 shares of company stock worth $40,486,151. 16.01% of the stock is owned by company insiders.

Hedge Funds Weigh In On Kymera Therapeutics

Institutional investors have recently modified their holdings of the business. PNC Financial Services Group Inc. raised its holdings in Kymera Therapeutics by 506.6% during the 2nd quarter. PNC Financial Services Group Inc. now owns 922 shares of the company’s stock worth $40,000 after buying an additional 770 shares during the period. Smartleaf Asset Management LLC boosted its holdings in shares of Kymera Therapeutics by 382.0% in the fourth quarter. Smartleaf Asset Management LLC now owns 535 shares of the company’s stock valued at $42,000 after buying an additional 424 shares during the period. Larson Financial Group LLC increased its position in shares of Kymera Therapeutics by 81.5% during the third quarter. Larson Financial Group LLC now owns 777 shares of the company’s stock worth $44,000 after acquiring an additional 349 shares in the last quarter. Osaic Holdings Inc. increased its position in shares of Kymera Therapeutics by 18,050.0% during the second quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock worth $48,000 after acquiring an additional 1,083 shares in the last quarter. Finally, Bessemer Group Inc. raised its holdings in shares of Kymera Therapeutics by 652.0% during the third quarter. Bessemer Group Inc. now owns 940 shares of the company’s stock worth $53,000 after acquiring an additional 815 shares during the period.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.